Study identifies a new class of drug targets for aggressive leukemia

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is deleted or removed, the cancer cells are sent into overdrive and die, finds a Yale-led study published in Science Signaling.